Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938740 · ClinicalTrials.gov registry record · Phase 2
Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec
A Phase 2 study, sponsored by Diasome Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03938740: Completed Phase 2 study, sponsored by Diasome Pharmaceuticals.
NCT03938740 is a Phase 2 study that has completed, run by Diasome Pharmaceuticals. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03938740, a Phase 2 study, has completed, sponsored by Diasome Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Multi-center, open-label, multiple dose safety, tolerability and efficacy study
Primary Outcome
Basal, bolus and total insulin doses (UOM=units) during the last 2 weeks of the treatment period
Interventions
- DRUG HDV-Insulin Lispro and Insulin Degludec (-40%)
- DRUG HDV-Insulin Lispro and Insulin Degludec (-10%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2020-03-18 |
| Phase | Phase 2 |
What the finished NCT03938740 record still lists
NCT03938740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which HDV-Insulin Lispro and Insulin Degludec (-40%) is the first listed.
NCT03938740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03938740 about?
NCT03938740 is a clinical study titled "Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec". Multi-center, open-label, multiple dose safety, tolerability and efficacy study
What is the current status of trial NCT03938740?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2019-03-18. Estimated completion is 2020-03-18.
What interventions are being tested in trial NCT03938740?
The interventions under investigation include: HDV-Insulin Lispro and Insulin Degludec (-40%) (DRUG), HDV-Insulin Lispro and Insulin Degludec (-10%) (DRUG).
Who is sponsoring clinical trial NCT03938740?
This trial is sponsored by Diasome Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03938740's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI